FDA third-party review programme could pay off
This article was originally published in Clinica
The FDA's third-party review programme has been unsuccessful mainly because companies have been reluctant to pay a fee when the agency reviews their product free of charge. Nonetheless some companies find that paying for a third-party review can be worthwhile in the long run, as they told a conference sponsored last week by the Health Industry Manufacturers Association on getting to market sooner.
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.